A UConn Health obesity specialist works through eight common GLP-1 myths
Dr. Jason Schneider says most misconceptions about GLP-1 medications trace back to an outdated view of obesity itself, and he walks through what the research does and does not say.
Few medicines have drawn as much attention, or as much bad information, as the GLP-1 drugs. UConn Today put eight of the most common claims to Dr. Jason Schneider, an OB/GYN at UConn Health who is board certified in obesity medicine, and published his answers as a fiction-versus-fact walkthrough. His argument across all eight is that the misconceptions share one root, which is an outdated picture of what obesity is.
The idea underneath most of the myths
Schneider said that for decades obesity was treated primarily as a failure of willpower, and that the science now describes something different. He characterizes it as a complex chronic disease shaped by genetics, hormones, metabolism, brain signaling and environment. In his framing, the medications did not change obesity itself, they changed what treating it can look like.
That reframing is what he returns to on the question of whether taking a GLP-1 counts as cheating. He noted that nobody describes a patient as cheating for taking medication for high blood pressure or diabetes, and said obesity deserves the same medical respect. He was clear that the drugs do not replace nutrition or exercise, describing them instead as one tool that helps patients get past biological barriers.
What the drugs act on
GLP-1 is a hormone the body releases after eating, and Schneider said it signals to several organs at once, including the brain, stomach and pancreas. The medications slow how quickly food leaves the stomach, which extends the feeling of fullness, and they also act on the appetite centers of the brain.
He pointed to one effect patients report often, which is a drop in what many of them call food noise, the constant mental background chatter about food and cravings. Researchers are now looking at that effect beyond obesity, he said, because the drugs appear to touch some of the same brain pathways tied to craving and reward.
Track record and side effects
On the claim that the drugs are too new to judge, Schneider noted that GLP-1 medicines were treating type 2 diabetes for years before most people heard of them for weight loss, and that the clinical research covers thousands of patients over close to two decades. He was direct that they are not right for everyone and that real safety considerations exist. He named a personal or family history of medullary thyroid cancer and Multiple Endocrine Neoplasia syndrome type 2 as conditions that call for a careful conversation with a physician.
On side effects, he said social media amplifies the extremes, because a person having a hard time is far likelier to post than the many who tolerate the drug without incident. The most common problems he listed are digestive, including nausea, constipation, diarrhea and acid reflux. He said those often ease over time or can be managed by adjusting the dose, changing eating habits or slowing the pace of dose increases, all of which he framed as reasons for continued contact with a clinician.
Muscle, and what happens after stopping
Schneider said some muscle loss can accompany any substantial weight loss, whether it comes from dieting, surgery or medication, and that it is not inevitable. He said strength training, adequate protein and regular physical activity matter more during that period, and that the aim is not the number on the scale but preserving muscle and physical function while health improves.
On regaining weight after stopping, he again drew the chronic-disease comparison. When a medicine controlling blood pressure, blood sugar or asthma stops, the underlying condition tends to return, and he said obesity behaves similarly. Some patients may stay on long-term treatment, he said, while others move to different therapies as newer options arrive.
The prescription is not the whole treatment
The myth Schneider pushed back on hardest was that an online prescription is all a patient needs. He described obesity medicine as ongoing monitoring rather than a weekly injection, covering nutrition, hydration, protein, physical activity, sleep and lab values, with dose adjustments for some patients and referrals to a registered dietitian or other specialists for others. He warned that losing weight too fast or eating too little can produce nutritional deficiencies and muscle loss when nobody is supervising.
What he expects next
Schneider called the current drugs one of the largest advances in obesity treatment in decades and also only a beginning. He pointed to research on medicines targeting several metabolic pathways at once, oral alternatives to injections, and approaches matched more closely to individual patients. The shift he singled out as most important is treating obesity based on the biology of the disease rather than on older assumptions.
GLP-1 medicines are prescription-only. Eligibility, dosing, risks and side effects are matters for the product label and a prescriber, and every claim above is Schneider’s as reported by UConn Today.
General information, not medical advice. Care decisions are between you and a licensed prescriber.